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Abstract
Introduction: Primary hyperparathyroidism is a common endocrine disorder characterized by elevated parathyroid
hormone levels, which cause continuous osteoclastic bone resorption. Giant cell tumor of bone is an expansile
osteolytic tumor that contains numerous osteoclast-like giant cells. There are many similarities in the radiological
and histological features of giant cell tumor of bone and brown tumor. This is a rare benign focal osteolytic
process most commonly caused by hyperparathyroidism.
Case presentation: We report the unusual case of a 40-year-old Caucasian woman in which primary
hyperparathyroidism was diagnosed after surgical ablation of a costal mass. The mass was suspected of being
neoplastic and histopathology was compatible with a giant cell tumor of bone. On the basis of the biochemical
results (including serum calcium, phosphorous and intact parathyroid hormone levels) primary hyperparathyroidism
was suspected and a brown tumor secondary to refractory hyperparathyroidism was diagnosed.
Conclusions: Since giant cell tumor is a bone neoplasm that has major implications for the patient, the standard
laboratory tests in patients with bone lesions are important for a correct diagnosis.
Introduction
Primitive hyperparathyroidism (PHPT) is the third most
common endocrine disorder after diabetes mellitus and
thyroid dysfunction [1]. The estimated incidence of
c a s e so fP H P Ti s0 . 2 %t o0 . 3 %[ 2 ] .T h ed i a g n o s i so f
PHPT has classically been based on the demonstration
of high plasma calcium and low plasma phosphorus
concentrations. In recent years, however, it has been
recognized that patients with PHPT may present with
plasma calcium concentrations within the normal range
[3]. About 75% to 80% of cases of PHPT are diagnosed
when a routine assay shows hypercalcemia in patients
who are asymptomatic or during evaluation for osteo-
porosis. Surgical ablation is the treatment of choice for
PHPT. Persistent hyperparathyroidism leads to altered
osseous metabolism involving bone resorption and tis-
sue changes that are collectively known as osteitis
fibrosa cystica (OFC) [3]. Today, < 5% of patients
display evidence of OFC [4]. Osteitis fibrosa cystica is
characterized by the presence of subperiosteal resorption
in the digits, skull and long bones, diffuse osteopenia,
and brown tumor [5].
Brown tumor is an extremely rare osseous lesion that
constitutes a focal manifestation of OFC induced by
hyperparathyroidism, independently of its cause. The
reported prevalence of brown tumors is 0.1%, and they
have been reported to occur in 4.5% of patients with
PHPT and in 1.5% to 1.7% of those with secondary dis-
ease [6,7]. The disease can manifest itself at any age, but
is more common among people older than 50 years,
and is three times more common in women than in
men [8]. Brown tumor may be the first clinical sign of
hyperparathyroidism. Histologically, brown tumors are
made up of mononuclear stromal cells mixed with mul-
tinucleated giant cells, among which recent hemorrhagic
infiltrates and hemosiderin deposits (hence the brown
color) are often found [9,10]. Brown tumors may appear
in any of the bones [11]. However, when the same type
of lesion is found in patients without PHPT, the differ-
ential diagnosis becomes more complex.
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brown tumor, a benign osteolytic process, are similar to
those of giant cell tumor (GCT) of bone. Giant cell
tumor of bone is an uncommon primary bone tumor
that accounts for around 5% of all primary bone tumors
[12]. Giant cell tumor is a locally aggressive tumor char-
acterized by a high number of multinuclear giant cells
that exhibit the features of mature osteoclasts [13].
Clinically, most patients with GCT are asymptomatic or
present with bone pain due to enlargement of the
tumor. Malignant transformation of GCT is a rare
event, occurring in less than 1% of all cases [14]. The
treatment of primary GCT is essentially surgical [12].
The differential diagnosis is based on biochemical
analysis.
Here, we report the case of a patient with an inciden-
tally discovered costal mass, the diagnostic investigation
of which led to an unexpected diagnosis.
Case presentation
We describe the case of a 40-year-old Caucasian woman
who had first been examined at the Department of
Internal Medicine of our University Hospital three years
ago for a Reynaud-like disorder. Her medical history
was unremarkable except for an oligomenorrhea since
she was 26 years of age. A physical examination revealed
a fair condition. A chest X-ray showed a peripheral
lesion, approximately 8 cm in diameter, of the third
right rib with cortical expansion; this was confirmed by
a contrast tomography scan. The lesion was associated
with an area of bone rarefaction of the lamina of L2.
The bone mass was suspected of being a neoplastic
lesion. Subsequently,
m99Tc bone scintigraphy revealed a
hyper-metabolic focus in the rib and in the medial con-
dylus of the right femur, while an magnetic resonance
imaging (MRI) scan showed an aneurysmal cystic bone
lesion. Costal biopsy showed numerous osteoclast-like
giant plurinuclear cells, without necrosis, mitoses or his-
tological signs of malignancy; a picture compatible with
GCT of bone. Six months after diagnosis, the mass was
surgically removed and local curettage was performed,
with excision of the right major pectoralis and part of
the II, III and IV right ribs. Histology showed a neo-
plasm with a solid structure made up of bland mono-
nuclear stromal cells and an osteoclast-type giant cell-
rich component, a picture compatible with GCT.
On gross examination, the surgical specimen consisted
of a soft, well circumscribed endothoracic mass of 6 ×
4.5 × 2.2 cm, with a tan and fleshy cut surface, which
c o n g l o b a t e dt w or i b s( 1 1c ma n d5 . 5c mi nl e n g t h ) .O n
microscopic examination, the tumor was seen to be
composed of a large number of single multinucleated
giant cells diffusely distributed on a background of spin-
dle-shaped, oval or polygonal mononuclear cells; these
latter cells were characterized by abundant eosinophilic
cytoplasm and oval nuclei without atypia. No aggregates
of giant cells were observed. Necrosis and areas of
hemorrhage were not observed. The mononuclear com-
ponent displayed a low mitotic index (6/10 high-power
field [HPF]) (Figure 1).
One month after surgery, during the first medical and
laboratory follow-up examination, an increase in serum
calcium (3.6 mmol/L) and alkaline phosphatase (ALP:
501 U/L) levels was found. Our patient’s parathyroid
function was found to be elevated (parathyroid hormone
[PTH]: 712 ng/L). Our patient was referred for endo-
crine evaluation two months after surgery. Review of
her medical records revealed hypercalcemia, which had
been underestimated at the first examination. Her family
history was negative for parathyroid and other endocrine
diseases. PHPT was suspected. No cervical masses were
palpable. Neck ultrasonography identified a round lesion
located behind and below the right thyroid lobe and
compatible with an enlarged parathyroid gland, whereas
the thyroid was normal (Figure 2). A
99 mTc-sestamibi
scan revealed a hyper-functioning area in the upper
right portion of the thyroid bed, which was suspected of
being an underlying parathyroid adenoma (Figure 3).
Cytological examination of a fine-needle aspiration
biopsy of the nodular lesion was compatible with a para-
thyroid adenoma. Sequencing of the multiple endocrine
neoplasia (MEN)-1 gene proved normal. All biochemical
data observed before parathyroidectomy are reported in
Table 1 and in the legend to Figure 2. A mini-invasive
parathyroidectomy was scheduled. Histology confirmed
the diagnosis of adenoma of the right inferior parathyr-
oid gland. Post-operative laboratory tests showed normal
levels of serum calcium (2.3 mmol/L) and PTH (80 ng/
L). After a review of bone slices, the final diagnosis of
the bone disease was a brown tumor secondary to prob-
ably long-standing underestimated PHPT. At present,
one year later, our patient is free from symptoms and
dual-emission X-ray absorptiometry (DXA) has shown
that her bone density has improved (Table 1).
Discussion
Primitive hyperparathyroidism involves a heterogeneous
group of patients with various symptoms and pathologi-
cal conditions.
Brown tumor is an unusual non-neoplastic lesion
resulting from abnormal bone metabolism in hyperpar-
athyroidism and represents a reparative cellular process
[15] that arises from foci of OFC, the end stage of a
bone-remodeling condition. Brown tumor is mainly due
to secondary hyperparathyroidism in patients with renal
insufficiency, but it has also been described as an extre-
mely rare manifestation of PHPT [11], usually resulting
from PTH overproduction by adenomas [16] or
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lar manifestation of PHPT appears in advanced stages of
the disease. In contrast with these previous reports, in
our patient’sc a s et h e r ew a sn oe v i d e n c eo fa d v a n c e d
end-stage disease. Moreover, our patient was only 40
years of age and presented with only slight osteopenia
without other symptoms or signs of malnutrition. How-
ever, she showed typical laboratory findings of PHPT.
Increased PTH levels induce the proliferation and dif-
ferentiation of pluripotent bone-marrow cells into osteo-
blasts and induce the migration and differentiation of
monocytes into osteoclasts; the increased number of the
latter in the bone tissue [3,6] causes bone resorption to
Figure 1 Histopathological analysis of the surgical specimens.
Top: a solid mass with diffuse infiltration and destruction of bone
tissue (hematoxilin and eosin (H&E), original magnification 4×).
Center: the solid mass is composed of numerous multinucleated
giant cells in a background of middle-sized cells (H&E, original
magnification 20×). Bottom: at higher magnification, the
background spindle-cell component is seen to be composed of
mononuclear spindle-shaped or oval-shaped cells, with eosinophilic
cytoplasm and oval nuclei without atypia (H&E, original
magnification 40×).
Figure 2 Neck ultrasonography images obtained about 21
months previously, demonstrating a solid cervical mass of 14
× 16 × 27 mm, with intra-lesional vascularization, under the
right thyroid lobe. After fine-needle aspiration biopsy (FNAB),
parathyroid hormone (PTH) evaluation on fine-needle washing was
550 pg/mL; this value was higher than our institutional standard
cut-off value of 132 pg/mL [30].
Vera et al. Journal of Medical Case Reports 2011, 5:596
http://www.jmedicalcasereports.com/content/5/1/596
Page 3 of 6predominate over the formation of new bone tissue.
Brown tumor therefore involves a combination of osteo-
blastic and osteoclastic activity.
Brown tumors were first reported about two decades
ago in 1.5% to 1.7% of patients with secondary hyper-
parathyroidism and in 3% of those with PHPT [6,18].
Our patient’s case of PHPT is probably sporadic, as
the majority of parathyroid tumors are sporadic. Only
5% are associated with hereditary endocrine tumor syn-
drome, which includes such diseases as MEN-1, MEN-2,
familial benign hypocalciuric hypercalcemia and familial
isolated PHPT.
These lesions may appear in any part of the skeleton
and one or more bones may be involved. Lesions are gen-
erally located in areas of intense bone resorption [19].
Localized brown tumors are difficult to diagnose
because they present clinically and radiologically as
expansile multi-locular masses. The upper end of the
tibia is the most common site of these lesions; unusual
sites include the pelvic bone, mandible, ribs, femur and
vertebral body.
In our patient, serum 25-hydroxyvitamin D (25[OH]D)
was low, and it is well known that, in asymptomatic
PHPT, low 25[OH]D levels are associated with increased
disease activity [20]. The tumors may cause pain and/or
fractures. Symptoms depend on the size and location of
the lesions. In other cases, lesions have been asympto-
matic, the diagnosis following incidental radiological
detection.
Histopathological analysis of the osseous lesion is
needed in order to confirm the diagnosis of a brown
tumor. As brown tumors exhibit no pathognomonic
histological changes, it may be very difficult to distin-
guish a brown tumor from other giant-cell tumors,
even on histological examination. In our patient, the
histological findings suggested a giant-cell expanding
bone lesion. It is important to point out that brown
tumors are non-neoplastic lesions that are very simi-
l a rt oG C T ;i nt h ec o n t e x to fP H P T ,t h e ya r ec o n s i d -
ered reparative granulomas and do not have the
malignant or neoplastic potential of true giant-cell
lesions.
On X-ray imaging, brown tumors appear as lytic
lesions with tortuous contours. Concurrent changes,
such as osteopenia, a ‘salt-and-pepper’ bone appearance
and subperiostal bone resorption, suggest OFC. Tomo-
graphy shows an osseous mass and areas that appear
cystic [21]. MRI may be better able to determine the
presence of cysts. On
99 mTc-sestamibi, isolated hyper-
metabolic lesions and the simultaneous hypercaptation
of bone lesions and parathyroid adenomas have been
described [22].
The main differential diagnosis is with GCT [6,18],
which is a highly vascular lesion. The radiological
appearance and, even more so, the histology of GCT
may closely mimic brown tumor, as in our patient. As it
is very difficult to distinguish brown tumors from other
giant-cell lesions histologically or radiologically, a defini-
tive diagnosis is only possible on comparing the clinical
manifestations and radiological and laboratory test
results that differentiate the lesions. Thus, the clinical
diagnosis is made in relation to PHPT [7,10].
Figure 3 Cervical scintigraphy obtained at the baseline (A) and
two hours after (B) 185 mBq of
99 mT-sestamibi injection about
22 months previously; accumulation of the isotope reflects the
hyperfunctioning parathyroid adenoma.
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to treat PHPT, which may be performed by means of
parathyroidectomy. The effect of parathyroidectomy on
brown tumors depends on their composition [23].
After treatment of the underlying metabolic disorder,
the regression or complete remission of brown tumors
has been well documented [24] in primary and second-
ary hyperparathyroidism. Patient age appears to be an
important factor in predicting the time required for
brown tumors to regress. Several authors consider
parathyroidectomy the only correct therapy [24]. How-
ever, several cases have been reported of brown tumors
that grew after parathyroidectomy or normalization of
PTH levels [25]. In these cases, resection of the brown
tumor should be the treatment of choice. Some
authors [26] believe that bone lesions reappear sponta-
neously following removal of the diseased parathyroid
gland; others [27] recommend initial treatment with
systemic corticosteroids to reduce tumor size, followed
by surgical removal of the residual lesion. Surgical
resection and decompression of brown tumors should
be considered if the patient is symptomatic [28]. In
cases in which lesions persist for more than six
months, or there is disruption of the function of the
affected organ, or growth despite adequate metabolic
control, some authors [25] have recommended tumor
curettage and associated enucleation. Finally, vitamin
D improves serum PTH levels, and medical treatment
based on high doses of vitamin D is effective in many
cases of brown tumor [29].
Conclusions
In summary, we report the case of a 40-year-old woman
with the association of brown tumor and a single para-
thyroid adenoma, in whom a bone neoplasm was first
suspected. The correct diagnosis was reached only later,
despite the many clinical manifestations. Radiograph
studies showed a combination of typical changes. This
case highlights the many similarities between GCT and
brown tumor.
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Table 1 Some laboratory data and T scores data from dual-emission X-ray absorptiometry analysis performed before
and after parathyroidectomy
Admission Before bone
tumor surgery
After bone
tumor surgery
Before
parathyroidectomy
After
parathyroidectomy
1 year post-
parathyroidectomy
Ca (mmol/L), normal value
2.1 to 2.7
3.7 3.6 3.6 3.2 2.3 2.3
P (mmol/L), normal value
0.81 to 1.45
0.55 0.48 0.68 0.48 - 0.81
ALP (U/L), normal value 98 to
280
347 501 423 224 - 192
PTH (ng/L), normal value 17
to 73
- - 712 873 88 80
Creatinine (μmol/L), normal
value 45 to 120
70 - - 70 - -
25[OH]D (μg/L), normal value
6t o4 6
- - - 13 8.2 9.9
1,25(OH)2D (pmol/L), normal
value 48 to 110
- - - 212.3 70.7 101.7
Osteocalcin (μg/L), normal
value 6.5 to 42.3
- - - 60.3 - 14.1
T-score, L2 to L4 - - - -2.48 -1.63 -1.25
T-score, femoral - - - -1.91 -1.29 -0.99
1,25(OH)2D, 1,25-dihydroxyvitamin D3; 25[OH]D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; PTH, parathyroid hormone.
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